Skip to main content
Let's spread the word about Immunotherapy! Click to share this page with your community.

img_table6_Adjuvant.pngAdjuvant immunotherapies can help produce a greater immune response

How does it work?

  • Adjuvant immunotherapies are substances that are either used alone or combined with other immunotherapies to boost the immune response even more
  • Adjuvant immunotherapies can improve responses to therapeutic cancer vaccines that require the work of T cells or other immune cells
  • Some adjuvant immunotherapies use ligands—molecules that can bind to protein receptors—to boost immune responses

For which cancers is it currently being used or studied?

  • Bacillus Calmette-Guérin (BCG) is FDA approved to treat superficial bladder cancer
  • Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine that stimulates dendritic cells to develop, and is often used as an adjuvant with therapeutic cancer vaccines, including those for prostate and pancreatic cancer
  • An adjuvant immunotherapy called Montanide is currently being used in vaccine trials for a number of cancers
  • Toll-like receptors (TLRs) are used to enhance the body’s immune response, and have shown effectiveness in brain, kidney, lung, colon, pancreatic, prostate, ovarian and breast cancer

*Immunotherapy results may vary from patient to patient.